Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIOSEUTICA B.V. has 2 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 2 distinct examiners and 2 distinct art units, indicating separate examination settings within the current docket.
FERNANDEZ, SUSAN EMILY is the busiest examiner, with 1 pending matter. Counsel should prepare application-specific responses and avoid treating the two actions as though they arose from one examination assignment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18675187 | STABLE GEL FORMULATIONS FOR THE TREATMENT OF ACNE VULGARIS | FERNANDEZ, SUSAN EMILY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18675187 | STABLE GEL FORMULATIONS FOR THE TREATMENT OF ACNE VULGARIS | FERNANDEZ, SUSAN EMILY | — |
| 18577782 | A PROCESS FOR THE PRODUCTION OF AMCIPATRICIN DIASCORBATE AND THE USE OF THE SAME FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS RESISTANT TO TRADITIONAL ANTIFUNGAL AGENTS | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18675187 | STABLE GEL FORMULATIONS FOR THE TREATMENT OF ACNE VULGARIS | FERNANDEZ, SUSAN EMILY | 1651 | §101§103§112 | Final Rejection | — | Pending | May 28, 2024 |
| 18577782 | A PROCESS FOR THE PRODUCTION OF AMCIPATRICIN DIASCORBATE AND THE USE OF THE SAME FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS RESISTANT TO TRADITIONAL ANTIFUNGAL AGENTS | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Jan 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOSEUTICA B.V. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Susan Emily Fernandez has the most, with 1 of BIOSEUTICA B.V.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
